The Top 5 Biosimilar Articles for the Week of May 12

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.

Number 4: Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

Number 3: Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.

Number 2: Alvotech/Teva and Biocon Biologics advanced US biosimilar access with FDA interchangeability for ustekinumab biosimilars, Selarsdi and Yesafili, plus broad 2025 formulary coverage for Biocon’s Yesintek.

Number 1: Sarfaraz K. Niazi, PhD, discusses US Senator Rand Paul's Expedited Access to Biosimilars Act, which aims to streamline the biosimilar approval process by eliminating redundant clinical study requirements, potentially lowering drug prices and improving access to life-saving treatments.

To read all of these articles and more, visit centerforbiosimilars.com.